The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.

Vaxiion Therapeutics Announces Completion of Phase 1a Dose Escalation and Initiation of a Phase 1b Dose Expansion Study for Intralesional Administration of VAX014 in Combination with PD-1 Directed ...

Pelareorep combined with atezolizumab achieved a 29% ORR in heavily pretreated metastatic SCAC patients, significantly improving historical benchmarks. The combination therapy demonstrated a median ...

The fight against cancer is undergoing a paradigm shift with the emergence of innovative strategies in Cancer Immunity & Immunotherapy. These approaches harness the body's own immune system to ...

A landmark study headed by researchers at Yale School of Medicine and at Fred Hutchinson Cancer Center has revealed that autoantibodies (AAbs)—immune proteins traditionally associated with autoimmune ...

Programmed death-ligand 1 (PD-L1) is a crucial immune checkpoint ligand that inhibits antitumor immunity by engaging PD-1 on T cells, and checkpoint blockade has become a pillar of anticancer therapy.

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed a novel cancer immunotherapy strategy that forces tumors to expose ...